晚期神经母细胞瘤的免疫化疗

Immunochemotherapy in advanced neuroblastoma.

作者信息

Necheles T F, Rausen A R, Kung F H, Pochedly C

出版信息

Cancer. 1978 Apr;41(4):1282-8. doi: 10.1002/1097-0142(197804)41:4<1282::aid-cncr2820410411>3.0.co;2-h.

DOI:10.1002/1097-0142(197804)41:4<1282::aid-cncr2820410411>3.0.co;2-h

Abstract

Twenty-two children with advanced (Stage III and IV) neuroblastoma have been treated in a nonrandomized fashion, half with a three-drug regimen consisting of vincristine, adriamycin, and cyclophosphamide, and half with this same drug combination plus the nonspecific immunostimulatory agent, MER/BCG. The addition of MER to the three-drug combination appeared to improve the duration of survival in this pilot study. The median duration of response was less than one year in the combination chemotherapy alone arm. The median duration of complete remission in children treated with the addition of MER has yet to be reached at 24 months.

摘要

22名患有晚期（Ⅲ期和Ⅳ期）神经母细胞瘤的儿童接受了非随机治疗，一半儿童采用由长春新碱、阿霉素和环磷酰胺组成的三联疗法，另一半儿童采用相同的药物组合加非特异性免疫刺激剂MER/卡介苗。在这项初步研究中，三联药物组合中添加MER似乎能延长生存期。仅接受联合化疗组的中位缓解持续时间不到一年。添加MER治疗的儿童的完全缓解中位持续时间在24个月时仍未达到。